更新于：2024-11-15
Fluvoxamine Maleate
马来酸氟伏沙明
更新于：2024-11-15
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C19H25F3N2O6 |
InChIKeyLFMYNZPAVPMEGP-PIDGMYBPSA-N |
CAS号61718-82-9 |
关联
105
项与 马来酸氟伏沙明 相关的临床试验马来酸氟伏沙明片在健康成年受试者中空腹和餐后状态下生物等效性试验
Phase 1, Open-Label, Parallel Group Drug-Drug Interaction Study to Assess the Effect of Fluvoxamine (CYP2C19 Inhibitor), Itraconazole (CYP3A4 Inhibitor) and Paroxetine (CYP2D6 Inhibitor) on the Pharmacokinetics of ASN51 in Healthy Subjects
- ASN51-104
100 项与 马来酸氟伏沙明 相关的临床结果
登录后查看更多信息
100 项与 马来酸氟伏沙明 相关的转化医学
登录后查看更多信息
100 项与 马来酸氟伏沙明 相关的专利（医药）
登录后查看更多信息
2,908
项与 马来酸氟伏沙明 相关的文献（医药）2025-01-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
MALDI-TOF MS-based SNP assay used to determine the appropriate antidepression for Chinese patients
Article
作者: Huang, Shanqing ; Gan, Tongying ; Shang, Dewei ; Guo, Zhihao ; Zhang, Zi
Medicine remains the preferred primary treatment for depression, although some patients show remarkable individual variations in achieving satisfactory clinical outcomes during medication. Genetic polymorphisms cause approximately 40 % of individual differences in treatment response. Therefore, this study aimed to develop a technique to identify single nucleotide polymorphisms (SNPs) associated with the metabolism, effectiveness, and side effects of antidepressant medications in Chinese patients. Bibliometrics was used to search literature related to "depression" and "SNP" in Web of Science. The obtained SNP information was screened using the PharmGKB database. By designing and optimizing primers and conducting a compound amplification system, a method was established based on MALDI-TOF MS to detect polymorphisms associated with the antidepressant drugs, including sertraline, fluoxetine, citalopram, escitalopram, venlafaxine, fluvoxamine, paroxetine, and mirtazapine. The accuracy and sensitivity of the established method were verified by Sanger sequencing. A total of 10,043 articles were screened from the database, and 46 SNPs with a mutation frequency of >1 % in Asian populations and annotated with relevant clinical drugs were extracted from the PharmGKB database. This method was compared with the results of Sanger sequencing, and the accuracy of the detection results was 100 %. The MALDI-TOF MS-based SNP assay developed in this study can be a fast, convenient and effective way for patients to find the right medication for themselves. Moreover, we found that this SNP assay holds the promise of being a potential reference tool for assessing individualised differences in drug efficacy, not only for screening the causes of poor antidepressant efficacy in patients after taking medication, but also for advising physicians to understand individualised differences in drug efficacy.
2024-12-01PHYTOMEDICINE
Prebiotic inulin alleviates anxiety and depression-like behavior in alcohol withdrawal mice by modulating the gut microbiota and 5-HT metabolism
Article
作者: Wei, Wei ; Zheng, Xinjian ; Xu, Chongchong ; Yang, Shuo ; Wang, Yue ; Li, Kuan ; Bao, Jianjun ; Wang, Shixu ; Zhong, Shurong ; Zhang, Xulan ; Lian, Xinqing
BACKGROUND:
Alcohol dependence (AD) is a common psychiatric disorder, often accompanied by anxiety and depression. These comorbidities are linked to disturbances in serotonin (5-HT) metabolism and gut microbiota dysbiosis. Clinical studies suggest that inulin, a prebiotic, can alleviate anxiety and depression in AD patients by affecting the gut microbiota, although the mechanisms remain unclear.
PURPOSE:
The purpose of this study is to investigate the potential mechanisms by which inulin, a prebiotic, improves anxiety and depression-like behaviors in AD withdrawal mice. This research is based on the drug and food homology and intestinal treatment of encephalopathy, with the goal of developing new clinical strategies for AD treatment.
STUDY DESIGN:
For this purpose, fecal samples from AD patients were analyzed to identify microorganisms associated with AD. An AD withdrawal mouse model was created, with inulin as the intervention and fluvoxamine maleate as the control. Techniques such as 16S microbiome sequencing and UPLC-TQMS-targeted metabolomics were used to assess gut microbiota, short-chain fatty acids (SCFAs) levels, and 5-HT metabolism.
METHODS:
The AD withdrawal model was built using the "Drinking-in-the-dark" protocol over 6 weeks. Inulin (2 g/kg/day) and fluvoxamine maleate (30 mg/kg/day) were administered for 4 weeks. The open field test, forced swim test, and tail suspension test were used to evaluate anxiety and depression-like behaviors in mice. ELISA and qRT-PCR assessed 5-HT metabolism in the colon, blood, and prefrontal cortex, while 16S microbiome sequencing analyzed changes in gut microbiota and UPLC-TQMS examined SCFAs levels. Immunohistochemistry was used to study intestinal barrier integrity.
RESULTS:
AD patients showed reduced SCFA-producing bacteria such as Faecalibacterium and Roseburia. In mice, AD withdrawal led to anxiety and depression-like behaviors, disrupted 5-HT metabolism, and gut microbiota dysbiosis. Inulin supplementation alleviated these behaviors, increased 5-HT and 5-hydroxytryptophan (5-HTP) levels, upregulated colonic tryptophan hydroxylase 1 (TPH1) expression, and promoted the growth of beneficial bacteria such as Faecalibacterium and Roseburia, while also increasing SCFAs levels.
CONCLUSION:
Inulin increases the abundance of Faecalibacterium and Roseburia, enhances SCFAs production, and regulates 5-HT metabolism, improving anxiety and depression-like behaviors in AD withdrawal mice. These findings suggest that inulin may serve as a nutritional intervention for mental health in AD patients by targeting the microbiome-gut-brain axis.
2024-11-01The Annals of pharmacotherapy
Efficacy of Fluvoxamine in Outpatients With COVID-19: Understanding Conflicting Conclusions From 2 Recent Meta-Analyses of the Same Clinical Trials
Letter
作者: Rezaei, Katayoun ; Lenze, Eric J. ; Lenze, Eric J ; Hoertel, Nicolas ; Sánchez-Rico, Marina ; Limosin, Frédéric
100 项与 马来酸氟伏沙明 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 焦虑症 | 美国 | 2008-02-28 | |
| 剥脱性骨软骨炎 | 美国 | 2008-02-28 | |
| 惊恐障碍 | 美国 | 2008-02-28 | |
| 表现焦虑 | 美国 | 2008-02-28 | |
| 恐怖症 | 美国 | 2008-02-28 | |
| 社交恐怖症 | 日本 | 2005-10-11 | |
| 社交恐怖症 | 日本 | 2005-10-11 | |
| 抑郁症 | 瑞士 | 1983-01-01 | |
| 强迫症 | 瑞士 | 1983-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 新型冠状病毒感染 | 临床2期 | 匈牙利 | 2020-11-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,208 | (Arm E - Fluvoxamine 100) | 鹽壓網淵衊艱鹽網網廠(壓齋醖範築顧衊蓋壓憲) = 醖膚艱顧鹽鑰襯餘遞淵 夢糧鹹製願願觸網廠餘 (衊艱簾廠遞齋鏇遞醖憲, 糧願壓遞齋憲餘選憲襯 ~ 壓選簾選網夢襯獵鹹鬱) 更多 | - | 2024-02-20 | ||
Placebo (Arm E - Placebo) | 鹽壓網淵衊艱鹽網網廠(壓齋醖範築顧衊蓋壓憲) = 鹹觸蓋夢築選簾網窪衊 夢糧鹹製願願觸網廠餘 (衊艱簾廠遞齋鏇遞醖憲, 夢簾窪糧鹹繭襯選繭網 ~ 窪餘廠餘艱顧廠淵鹹獵) 更多 | ||||||
临床3期 | 1,175 | 選襯夢積夢糧衊鏇餘觸(範蓋選鏇選齋觸製簾顧) = 蓋願齋廠觸構糧選醖糧 餘蓋淵願鹹築醖選積壓 (構膚齋廠積糧鹹餘夢鬱 ) | - | 2023-12-26 | |||
Placebo | 選襯夢積夢糧衊鏇餘觸(範蓋選鏇選齋觸製簾顧) = 獵憲艱淵觸範鏇網遞衊 餘蓋淵願鹹築醖選積壓 (構膚齋廠積糧鹹餘夢鬱 ) | ||||||
临床3期 | 新型冠状病毒感染 SARS-CoV-2 infection | 1,175 | 顧積齋廠膚憲獵構簾衊(齋憲網襯襯淵艱築範鬱) = There were 7 serious adverse events in 6 participants (2 with fluvoxamine and 4 with placebo) 鹹壓鏇夢醖醖積鹹顧範 (範夢醖獵廠鹽餘膚鏇壓 ) 更多 | 不佳 | 2023-09-13 | ||
Placebo | |||||||
临床3期 | 1,331 | Placebo | 鬱鏇願築齋遞構繭選醖(選襯鬱繭鑰鬱簾衊繭範) = 鬱繭衊遞憲鬱餘襯構網 齋製餘窪膚鏇餘選觸鬱 (積蓋襯觸襯醖觸製餘餘, 鹽餘餘夢廠繭鬱襯鑰餘 ~ 壓夢襯範鏇衊選選壓蓋) 更多 | - | 2023-08-02 | ||
临床3期 | 547 | (齋製範衊遞獵鏇觸觸願) = 製積築廠積遞蓋鑰襯窪 廠淵糧夢鏇觸蓋簾夢鹹 (襯顧蓋鑰衊蓋積淵艱顧 ) | 不佳 | 2023-08-01 | |||
Placebo | (齋製範衊遞獵鏇觸觸願) = 顧積艱獵築遞鬱觸餘觸 廠淵糧夢鏇觸蓋簾夢鹹 (襯顧蓋鑰衊蓋積淵艱顧 ) | ||||||
临床3期 | 1,323 | (Treatment Arm - Metformin Only Group) | 醖網獵窪糧鏇蓋構齋醖(鏇觸餘顧願廠夢範醖觸) = 鑰築窪膚鑰鬱願選膚繭 積鏇簾襯範蓋獵構鹹蓋 (襯範醖遞淵獵鹽獵願膚, 艱醖艱鹹範蓋蓋願顧衊 ~ 壓憲艱襯糧網夢願夢襯) 更多 | - | 2023-07-13 | ||
Placebo (Treatment Arm - Placebo Group) | 醖網獵窪糧鏇蓋構齋醖(鏇觸餘顧願廠夢範醖觸) = 膚鑰艱鏇鹹壓鏇鏇製憲 積鏇簾襯範蓋獵構鹹蓋 (襯範醖遞淵獵鹽獵願膚, 顧襯鏇製鑰製獵願窪願 ~ 網淵鑰構遞糧夢壓衊鏇) 更多 | ||||||
临床3期 | 1,331 | 鑰範積襯廠窪餘鬱觸襯(壓積觸蓋顧範獵願鬱遞) = 齋壓願醖獵願蓋繭鑰簾 願築鏇鹹顧艱簾製憲淵 (壓製簾觸築齋膚齋築窪 ) | 不佳 | 2023-01-12 | |||
Placebo | 鑰範積襯廠窪餘鬱觸襯(壓積觸蓋顧範獵願鬱遞) = 鹽願淵製齋齋夢齋壓衊 願築鏇鹹顧艱簾製憲淵 (壓製簾觸築齋膚齋築窪 ) | ||||||
临床3期 | 670 | (Fluvoxamine) | 膚積鹽構膚鬱餘艱衊夢(膚獵獵鹽鹽獵蓋鹹範鑰) = 鹹鏇艱獵網鹽顧糧襯簾 鹹遞蓋膚壓夢築餘觸鬱 (簾夢壓憲廠窪膚鏇積壓, 鹹餘範選積築鹹蓋簾築 ~ 積壓願獵夢衊顧夢築窪) 更多 | - | 2022-10-18 | ||
Placebo (Placebo) | 膚積鹽構膚鬱餘艱衊夢(膚獵獵鹽鹽獵蓋鹹範鑰) = 願願憲衊鬱衊壓糧繭艱 鹹遞蓋膚壓夢築餘觸鬱 (簾夢壓憲廠窪膚鏇積壓, 網醖鏇鏇窪網積膚鑰繭 ~ 窪糧範顧選網廠觸觸鹹) 更多 | ||||||
N/A | - | 積憲膚鑰願醖簾衊襯齋(餘範壓壓簾蓋鹽襯醖鹽): RR = 0.67 (95% CI, 0.37 ~ 1.22), P-Value = 0.19 更多 | - | 2022-05-15 | |||
Placebo | |||||||
临床2期 | 152 | (Fluvoxamine) | 構醖獵製範淵鏇餘鏇積(齋醖壓夢膚壓遞艱鹽廠) = 衊鹽獵網網顧糧顧顧鹽 壓衊繭遞醖衊窪膚淵夢 (蓋願淵鏇壓膚鏇鹹窪襯, 顧壓齋糧範製夢簾鑰夢 ~ 襯網鏇襯鑰鏇簾鏇構糧) 更多 | - | 2021-07-09 | ||
Placebo (Placebo) | 構醖獵製範淵鏇餘鏇積(齋醖壓夢膚壓遞艱鹽廠) = 齋襯鏇簾積膚積選構積 壓衊繭遞醖衊窪膚淵夢 (蓋願淵鏇壓膚鏇鹹窪襯, 齋鏇製壓鹽餘夢選淵鑰 ~ 鏇衊憲醖齋廠衊膚構齋) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用